| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
This chromogenic substrate targets serine proteases, particularly those with trypsin-like or related substrate specificity. The presence of the Z-protecting group (benzyloxycarbonyl) on the lysine residue ensures stability and specificity in biochemical assays. The peptide sequence D-Lys(Z)-Pro-Arg is designed to be recognized and cleaved by specific proteases, releasing the chromogenic pNA group.
|
|---|---|
| ln Vitro |
In vitro, D-Lys(Z)-Pro-Arg-pNA diacetate serves as a substrate for protease activity measurements. Upon enzymatic cleavage, the release of p-nitroaniline is monitored spectrophotometrically at 405 nm. The rate of pNA release is directly proportional to enzyme activity, allowing for precise kinetic analysis of protease function in various biological samples.
|
| ln Vivo |
In vivo activity data for D-Lys(Z)-Pro-Arg-pNA diacetate are not applicable, as this compound is a substrate used exclusively for in vitro enzymatic assays and not for therapeutic or in vivo pharmacological applications. Its utility is limited to biochemical and molecular biology research settings for measuring protease activity in cell lysates, plasma, or purified enzyme preparations.
|
| Enzyme Assay |
In vitro enzyme assays using D-Lys(Z)-Pro-Arg-pNA diacetate are performed by incubating the substrate with the enzyme of interest (e.g., trypsin, thrombin, or other serine proteases) in an appropriate buffer at optimal pH and temperature. The cleavage of the substrate releases p-nitroaniline, which is continuously monitored at 405 nm using a spectrophotometer or microplate reader. Initial reaction rates are calculated from the linear portion of the absorbance curve.
|
| Cell Assay |
Cell-based assays for D-Lys(Z)-Pro-Arg-pNA diacetate are typically performed using cell lysates or conditioned media rather than intact cells, as the substrate is designed for cell-free enzymatic analysis. Cell cultures are lysed, and the lysates are incubated with the substrate in a buffer system. Protease activity is quantified by measuring the absorbance at 405 nm. The substrate can also be used to assess protease activity in serum or plasma samples.
|
| Animal Protocol |
In vivo animal protocols for D-Lys(Z)-Pro-Arg-pNA diacetate are not applicable, as the compound is used exclusively for in vitro biochemical assays. The substrate is not administered to animals for pharmacological studies. Instead, it is used to measure ex vivo protease activity in biological samples collected from animal models, such as plasma, tissue homogenates, or bronchoalveolar lavage fluid.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for D-Lys(Z)-Pro-Arg-pNA diacetate are not applicable, as the compound is not used as a therapeutic drug but rather as a research reagent for in vitro enzymatic assays. The compound is typically dissolved in water or buffer immediately before use. Storage conditions are at -20degC, protected from moisture and light. No systemic pharmacokinetic properties have been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological information for D-Lys(Z)-Pro-Arg-pNA diacetate is not relevant for in vivo applications, as the compound is used only in cell-free and in vitro research settings. Standard laboratory safety precautions apply when handling the compound. No significant toxicity has been reported for its intended use as a chromogenic substrate. The compound is for research use only and not for human consumption.
|
| Additional Infomation |
D-Lys(Z)-Pro-Arg-pNA diacetate (Spectrozyme PCa) is a research-use chromogenic substrate not approved for clinical therapeutic applications. It is widely used in biochemistry and molecular biology for the study of serine protease activity, enzyme kinetics, and inhibitor screening. The compound serves as a valuable tool for understanding protease mechanisms and protein interactions within complex biological systems.
|
| Molecular Formula |
C35H51N9O11
|
|---|---|
| Molecular Weight |
773.833148241043
|
| Exact Mass |
773.37
|
| CAS # |
108963-70-8
|
| Related CAS # |
D-Lys(Z)-Pro-Arg-pNA;108963-69-5
|
| PubChem CID |
92044477
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
55
|
| Complexity |
1100
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC(=O)O.CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H](CCCCNC(=O)OCC2=CC=CC=C2)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC3=CC=C(C=C3)[N+](=O)[O-]
|
| InChi Key |
VMCWZMKBOZNVHX-ANSAKZOLSA-N
|
| InChi Code |
InChI=1S/C31H43N9O7.2C2H4O2/c32-24(10-4-5-17-36-31(44)47-20-21-8-2-1-3-9-21)29(43)39-19-7-12-26(39)28(42)38-25(11-6-18-35-30(33)34)27(41)37-22-13-15-23(16-14-22)40(45)46;2*1-2(3)4/h1-3,8-9,13-16,24-26H,4-7,10-12,17-20,32H2,(H,36,44)(H,37,41)(H,38,42)(H4,33,34,35);2*1H3,(H,3,4)/t24-,25+,26+;;/m1../s1
|
| Chemical Name |
acetic acid;benzyl N-[(5R)-5-amino-6-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-6-oxohexyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~2 mg/mL (~2.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2923 mL | 6.4614 mL | 12.9227 mL | |
| 5 mM | 0.2585 mL | 1.2923 mL | 2.5845 mL | |
| 10 mM | 0.1292 mL | 0.6461 mL | 1.2923 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
